期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
曲唑酮治疗阿尔茨海默病伴睡眠障碍患者的疗效及对患者认知功能的影响 被引量:5
1
作者 何卫亮 徐哲 +3 位作者 潘新根 杨守开 那万秋 陈浙丽 《中国现代医学杂志》 CAS 北大核心 2021年第12期63-68,共6页
目的探讨曲唑酮治疗阿尔茨海默病(AD)伴睡眠障碍患者的疗效及其对患者认知功能、海马体积、日常生活能力的影响。方法选取2018年10月—2019年10月在湖州市第三人民医院就诊的AD伴随睡眠障碍患者70例为研究对象。将70例患者随机分为观察... 目的探讨曲唑酮治疗阿尔茨海默病(AD)伴睡眠障碍患者的疗效及其对患者认知功能、海马体积、日常生活能力的影响。方法选取2018年10月—2019年10月在湖州市第三人民医院就诊的AD伴随睡眠障碍患者70例为研究对象。将70例患者随机分为观察组(口服多奈哌齐+曲唑酮)和对照组(口服多奈哌齐+唑吡坦),每组35例。用MRI扫描并计算海马体积。采用简易精神状态检查(MMSE)量表、蒙特利尔认知评估(MoCA)量表、日常生活活动(ADL)量表评估患者认知水平及日常生活能力。采用多导睡眠图(PSG)、匹兹堡睡眠治疗指数(PSQI)量表评估患者睡眠质量及疗效。结果观察组治疗前后总睡眠时间及睡眠效率提高的水平高于对照组(P<0.05),睡眠潜伏期、觉醒次数降低的水平高于对照组(P<0.05)。观察组左测海马头部体积降低的差值大于对照组(P<0.05)。两组治疗前后左侧海马体部、尾部及右侧海马头部、体部、尾部体积的差值比较,差异无统计学意义(P>0.05)。观察组患者治疗前后MMSE、MoCA及ADL评分提高的水平高于对照组(P<0.05)。观察组睡眠障碍临床疗效优于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论曲唑酮联合多奈哌齐治疗AD伴睡眠障碍可显著改善患者睡眠质量,提高疗效、认知功能,改善患者左侧海马头部萎缩,并具有良好的耐受性,值得进一步临床推广应用。 展开更多
关键词 阿尔茨海默病 曲唑酮 睡眠障碍 认知功能 海马体积
下载PDF
Interaction between serum inflammatory cytokines and brain-derived neurotrophic factor in cognitive function among first-episode schizophrenia patients
2
作者 Li-Jun Cui Li-Li Cai +3 位作者 wan-qiu na Rui-Long Jia Jie-Lin Zhu Xin Pan 《World Journal of Psychiatry》 SCIE 2024年第12期1804-1814,共11页
BACKGROUND The pathogenesis of cognitive impairment in schizophrenia(SCZ)remains unclear.Accumulating studies showed that inflammatory-immune dysregulation and altered brain derived neurotrophic factor(BDNF)levels pla... BACKGROUND The pathogenesis of cognitive impairment in schizophrenia(SCZ)remains unclear.Accumulating studies showed that inflammatory-immune dysregulation and altered brain derived neurotrophic factor(BDNF)levels play a crucial role in the psychopathology of SCZ.However,their association with cognitive dysfunction in first-episode SCZ patients has not been thoroughly investigated.AIM To explore the interaction effects between cognitive function and inflammatory cytokines and BDNF in first-episode SCZ.METHODS The current study is a cross-sectional case-control investigation that recruited 84 patients with first-episode SCZ(SCZ group)and 80 healthy controls(HCs group)at the Huzhou Third Municipal Hospital between August 2021 and September 2023.ELISA was employed to measure the serum levels of interleukin(IL)-1β,IL-4,IL-6,IL-10,and BDNF.The Chinese brief cognitive test(C-BCT)and the positive and negative syndrome scales were measured the severity of cognitive impairment and psychiatric symptoms.RESULTS Compared to the HC group,the SCZ group exhibited elevated IL-1βand IL-6 levels,decreased BDNF levels,and reduced C-BCT scores(all P<0.001).In SCZ,BDNF was negatively correlated with IL-6(r=-0.324,P<0.05).Information processing speed was negatively correlated with IL-6(r=-0.315,P<0.05)and positively with BDNF(r=0.290,P<0.05);attention,working memory,comprehensive ability,and executive function were negatively correlated with IL-1βand IL-6(all P<0.05)and positively with BDNF(all P<0.05).Multiple regression analysis showed IL-6 influenced C-BCT dimensions(β=-0.218 to-0.327,all P<0.05);attention and executive ability were influenced by IL-1β(β=-0.199 to-0.261,all P<0.05);comprehensive executive ability was influenced by BDNF(β=0.209,P<0.05).CONCLUSION Our findings suggested that interrelationships between immune dysfunction and neurotrophic deficiency might underlie the pathological mechanisms of cognitive impairments in first-episode SCZ patients. 展开更多
关键词 Brain-derived neurotrophic factor Inflammatory cytokines First-episode schizophrenia Cognitive function Proinflammatory cytokines Neuroinflammation Serum biomarkers
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部